Theravance Biopharma (NASDAQ: TBPH) reported Q1 EPS of ($1.32), $0.13 worse than the analyst estimate of ($1.19). Revenue for the quarter came in at $5.3 million versus the consensus estimate of $16.21 million.

For earnings history and earnings-related data on Theravance Biopharma (TBPH) click here.